A Review of the Pharmacokinetics of Abacavir

@article{Yuen2008ARO,
  title={A Review of the Pharmacokinetics of Abacavir},
  author={G. Yuen and S. Weller and G. Pakes},
  journal={Clinical Pharmacokinetics},
  year={2008},
  volume={47},
  pages={351-371}
}
  • G. Yuen, S. Weller, G. Pakes
  • Published 2008
  • Medicine
  • Clinical Pharmacokinetics
    • Abacavir is a carbocyclic 2′-deoxyguanosine nucleoside reverse transcriptase inhibitor that is used as either a 600-mg once-daily or 300-mg twice-daily regimen exclusively in the treatment of HIV infection. Abacavir is rapidly absorbed after oral administration, with peak concentrations occurring 0.63–1 hour after dosing. The absolute bioavailability of abacavir is approximately 83%. Abacavir pharmacokinetics are linear and doseproportional over the range of 300–1200 mg/day. To date, one study… CONTINUE READING
    View on Springer
    ncbi.nlm.nih.gov
    101 Citations
    Highly Influencial Citations
    7
    Background Citations
    33
    Methods Citations
    2
    Results Citations
    1

    Paper Mentions

    Blog Post
    ABACAVIR
    New Drug Approvals
    4 June 2019
    101 Citations
    Citation Type

    Citation Type

    PharmGKB summary: abacavir pathway
    • 4
    The pharmacokinetics of abacavir 600 mg once daily in HIV-1-positive pregnant women
    • 6
    Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-<36 months.
    • 22
    • PDF
    Plasma pharmacokinetics of once-daily abacavir- and lamivudine-containing regimens and week 96 efficacy in HIV-infected Thai children
    Population pharmacokinetics of abacavir in infants, toddlers and children.
    • 12
    Bioequivalence study of abacavir 300 mg tablets in healthy Thai male volunteers under fasting conditions
    • Highly Influenced
    Pharmacokinetics of nucleoside/nucleotide reverse transcriptase inhibitors for the treatment and prevention of HIV infection
    Abacavir Pharmacogenetics – From Initial Reports to Standard of Care
    • 34
    Abacavir/lamivudine fixed-dose combination antiretroviral therapy for the treatment of HIV
    • 15
    Clinical pharmacokinetics and pharmacodynamics of dolutegravir used as a single tablet regimen for the treatment of HIV-1 infection
    • 12

    References

    SHOWING 1-10 OF 88 REFERENCES
    Pharmacokinetics of Abacavir in HIV-1-Infected Patients with Impaired Renal Function
    • 29
    Safety and Single-Dose Pharmacokinetics of Abacavir (1592U89) in Human Immunodeficiency Virus Type 1-Infected Children
    • 52
    • PDF
    Multiple-Dose Pharmacokinetics and Pharmacodynamics of Abacavir Alone and in Combination with Zidovudine in Human Immunodeficiency Virus-Infected Adults
    • 47
    • PDF
    Pharmacokinetic and Pharmacodynamic Study of the Human Immunodeficiency Virus Protease Inhibitor Amprenavir after Multiple Oral Dosing
    • 90
    • PDF
    Safety and Pharmacokinetics of Abacavir (1592U89) following Oral Administration of Escalating Single Doses in Human Immunodeficiency Virus Type 1-Infected Adults
    • 56
    • PDF
    Population Pharmacokinetics and Pharmacodynamic Modeling of Abacavir (1592U89) from a Dose-Ranging, Double-Blind, Randomized Monotherapy Trial with Human Immunodeficiency Virus-Infected Subjects
    • 69
    • PDF
    A Phase I Study of Abacavir (1592U89) Alone and in Combination With Other Antiretroviral Agents in Infants and Children With Human Immunodeficiency Virus Infection
    • 39
    • PDF
    Single-Dose Pharmacokinetics and Safety of Abacavir (1592U89), Zidovudine, and Lamivudine Administered Alone and in Combination in Adults with Human Immunodeficiency Virus Infection
    • 60
    • PDF
    Methadone Blood Concentrations Are Decreased by the Administration of Abacavir Plus Amprenavir
    • 53
    Pharmacodynamics of Abacavir in an In Vitro Hollow-Fiber Model System
    • 31
    • PDF